, /PRNewswire/ -- According to WHO, 528 million people suffer from joint pain. Age, obesity, and sports can lead to cartilage wear and osteoarthritis. While surgery or implants are common treatments, with the accountable for about 30% of global joint replacements, regenerative medicine is emerging as more effective and less invasive.
In this field, the biotech company is born, resulting from the merger of the Spanish Regenera Activa Worldwide and the Italian Rigenera HBW. The company works with the patented Rigenera® technology, a unique and innovative minimally invasive treatment based on patient's own cells injected through micrografts. As a result, Remedi is now present in 70 countries and has a turnover of over .
"Our goal is to continue growing and double our turnover in two years. To achieve this, the U.S.
is key market where we are not yet present and where we are raising capital to set up our own distribution network" explains , Remedi's CEO. Today, Rigenera® technology is used by more than 10,000 doctors worldwide, and over 450,000 treatments have been performed with it. Simultaneously, the company has also started its distribution in , a market expected to help reach in turnover in 2025.
Rigenera® technology represents a radical change compared to current treatments, as it halts osteoarthritis and joint degeneration without resorting to prosthetics, relieving pain and improving the patients' life's quality. The procedure uses a combination of autologous (from the.
